Symptoms and medication.
The symptoms measured by the RTSS and MS were significantly reduced
three years post ILIT regardless of active allergen during the birch and
grass pollen seasons. The reduction was already evident during the first
season after ILIT, and the effect was sustained throughout the following
three years. When combining all three groups, RTSS was reduced from 12.2
to 7.4 (-39%) and from 11.2 to 6.5 (-42%) three years after treatment
during the birch and grass pollen seasons, respectively
(p<0.05, Fig. 2c-d, see Table S1 in the Supplementary
information). When combining MS data from all three treatment groups
together, it was significantly reduced from 9.4 before ILIT to 4.9
(-48%) and from 8.6 to 4.4 (-49%) three years after treatment during
the birch and grass pollen seasons, respectively (p<0.01, Fig.
2e-f. For levels of RTSS and MS see Table S1 in the Supplementary
information). There were no gender-related differences in improvement
(data not shown). The patients receiving ILIT in 2014 and 2015 responded
almost in the same way (data not shown).